Interestingly, there are no Big Pharma companies listed in the “Magnificent Seven.” Consequently, perfectly good companies like Pfizer (NYSE:PFE) are being overlooked, but that’s not bad news at all. If you appreciate a good value and like to collect dividends, stick around as today’s Pfizer stock analysis will bring you a “magnificent” pick for 2024.
Pfizer is in Wall Street’s doghouse, but don’t despair. At its current price, value seekers ought to relish the opportunity to buy PFE stock.
This post appeared first on InvestorPlace.